Stifel Nicolaus Reiterates a Buy Rating on Valeant Pharma

By Carrie Williams

In a report released yesterday, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on Valeant Pharma (NYSE: VRX), with a price target of $35. The company’s shares opened today at $17.35.

According to, Samimy is a 5-star analyst with an average return of 13.0% and a 54.0% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Corcept Therapeutics Inc, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Valeant Pharma is Hold and the average price target is $17.91, representing a 3.2% upside.

In a report issued on June 16, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $18 price target.

Based on Valeant Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $2.11 billion and quarterly net profit of $628 million. In comparison, last year the company earned revenue of $2.42 billion and had a GAAP net loss of $302 million.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S.